Abstract
The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a cAMP-regulated Cl- channel whose major function is to facilitate epithelial fluid secretion. Loss-of-function mutations in CFTR cause the genetic disease cystic fibrosis. CFTR is required for transepithelial fluid transport in certain secretory diarrheas, such as cholera, and for cyst expansion in autosomal dominant polycystic kidney disease. High-throughput screening has yielded CFTR inhibitors of the thiazolidinone, glycine hydrazide and quinoxalinedione chemical classes. The glycine hydrazides target the extracellular CFTR pore, whereas the thiazolidinones and quinoxalinediones act at the cytoplasmic surface. These inhibitors have been widely used in cystic fibrosis research to study CFTR function at the cell and organ levels. The most potent CFTR inhibitor has IC50 of approximately 4 nM. Studies in animal models support the development of CFTR inhibitors for antisecretory therapy of enterotoxin-mediated diarrheas and polycystic kidney disease.
Keywords: Chloride channels, cystic fibrosis, diarrhea, polycystic kidney disease, drug discovery.
Current Pharmaceutical Design
Title:CFTR Inhibitors
Volume: 19 Issue: 19
Author(s): Alan S. Verkman, David Synder, Lukmanee Tradtrantip, Jay R. Thiagarajah and Marc O. Anderson
Affiliation:
Keywords: Chloride channels, cystic fibrosis, diarrhea, polycystic kidney disease, drug discovery.
Abstract: The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a cAMP-regulated Cl- channel whose major function is to facilitate epithelial fluid secretion. Loss-of-function mutations in CFTR cause the genetic disease cystic fibrosis. CFTR is required for transepithelial fluid transport in certain secretory diarrheas, such as cholera, and for cyst expansion in autosomal dominant polycystic kidney disease. High-throughput screening has yielded CFTR inhibitors of the thiazolidinone, glycine hydrazide and quinoxalinedione chemical classes. The glycine hydrazides target the extracellular CFTR pore, whereas the thiazolidinones and quinoxalinediones act at the cytoplasmic surface. These inhibitors have been widely used in cystic fibrosis research to study CFTR function at the cell and organ levels. The most potent CFTR inhibitor has IC50 of approximately 4 nM. Studies in animal models support the development of CFTR inhibitors for antisecretory therapy of enterotoxin-mediated diarrheas and polycystic kidney disease.
Export Options
About this article
Cite this article as:
Verkman Alan S., Synder David, Tradtrantip Lukmanee, Thiagarajah Jay R. and Anderson Marc O., CFTR Inhibitors, Current Pharmaceutical Design 2013; 19 (19) . https://dx.doi.org/10.2174/13816128113199990321
DOI https://dx.doi.org/10.2174/13816128113199990321 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNA-mediated MMP Regulation: Current Diagnostic and Therapeutic Strategies for Metabolic Syndrome
Current Gene Therapy Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design Chronic Hepatitis C and Alcohol Abuse: The Single Center Experience of Novi Sad - Serbia
Reviews on Recent Clinical Trials Actions of Selected Cardiovascular Hormones on Arterial Stiffness and Wave Reflections
Current Pharmaceutical Design Implications of Nanotechnology in Healthcare
Nanoscience & Nanotechnology-Asia Nearly Half of Uncontrolled Hypertensive Patients could be Controlled by High-dose Titration of Amlodipine in the Clinical Setting: The ACHIEVE Study
Current Hypertension Reviews Obesity, Hypertension and Hypercholesterolemia as Risk Factors for Atherosclerosis Leading to Ischemic Events
Current Medicinal Chemistry The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design HDL Elevation and Lipid Lowering Therapy: Current Scenario and Future Perspectives
Recent Patents on Cardiovascular Drug Discovery Analysis of Metformin Dosage Formulations by Capillary Electrophoresis at Nano Scale Detection
Combinatorial Chemistry & High Throughput Screening Medicinal Chemistry of Potassium Channel Modulators: An Update of Recent Progress (2011-2017)
Current Medicinal Chemistry The Effects of Medications Used for the Management of Dyslipidemia on Postprandial Lipemia
Current Medicinal Chemistry Impact of Metabolic Risk Factors on COVID-19 Clinical Outcomes: An Extensive Review
Current Cardiology Reviews New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Contribution of Electrochemistry to the Biomedical and Pharmaceutical Analytical Sciences
Current Drug Delivery Obsessive-Compulsive Disorder in the Perinatal Period: A Review of the Literature
Current Psychiatry Reviews Imaging of Pancreatic Beta-Cell Signal-Transduction
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Intracellular Accumulation of Toxic Turn Amyloid-β is Associated with Endoplasmic Reticulum Stress in Alzheimer’s Disease
Current Alzheimer Research